entertainment -WSS

entertainment

author：fashion 2025-10-02 00:53:11 - browse：87287

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Readout LOUD podcast: ESMO highlights & Roivant's big deal

WSS

Bill would allow buprenorphine prescription for addiction via telehealth

Travis Kelce and the trap of celebrity vaccine endorsements

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

European regulators recommend Amylyx's ALS drug be rejected

All of Us, NIH's precision medicine initiative, gets a big boost

Medicare to cover more brain scans related to Alzheimer’s drugs

focus

entertainment

hotspot

Apple is now the first public company to be valued at $3 trillion

How doctors and nurses shape Google's AI

How one medical school became remarkably diverse

Prime Medicine says its gene editing passes test in monkeys

BioMarin wins approval for gene therapy to treat hemophilia A

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What is microchimerism and how does it affect maternal health?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Takeaways from AdvaMed, the largest medical devices conference

hotspot

Key Senate panel to consider PBM, drug pricing reform package

Brain injuries and the importance of a second opinion

Infant mortality in U.S. rose last year for first time in decades: CDC

How should state employee insurance handle Wegovy?

Inari Medical to buy amputation prevention company LimFlow

Humana CEO Bruce Broussard to step down in 2024

focus

hotspot

hotspot

entertainment